MEMBER LOGIN: Your Email: Password: Remember Me
Forgot Your Password or would like to register?
JNJ Johnson & Johnson
As Of 9/21/2018 7:12:00 PM
Current Price$142.88
Current Rating1
Return Since 10/2015
Johnson & Johnson 62.66 %
S&P 50052.40 %
VFS Rating Analysis
Market ReturnAverage
return vs market
Related Links
Company News
Earnings Call Transcripts
Options Chain
Options Pricing History
For current estimates, historical performance information and more, Log in to your account.

Monthly Performance and Prediction History
Below is the monthly performance history for this security and the monthly change as compared to the stock market for this security. When a row is highlighted in green, it is identifying a stock that the model predict will outperform the portfolio for that month. When a row is highlighted in red, it is identifying a stock that the model predicted will underperform for the month. No highlight indicates the model is neutral on the stock. These predictions are always recorded at the beginning of the month, and table below shows the resulting return for the month.
DateVFS RatingPredictionRating PriceSubsequent
% Increase
Market %
Increase *
8-01-20182 $132.522.32%3.19%-0.88%
5-01-20183 $126.49-4.72%2.43%-7.15%
4-01-20182 $128.15-1.30%0.52%-1.81%
3-01-20182 $129.88-1.33%-3.13%1.80%
* As measured by the performance of the S&P 500 for the month.

JNJ14See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ14J&J Files NDA for Erdafitinib in Urothelial Cancer Indication ( 8:05:00 AM
JNJ14Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again ( 7:10:00 AM
JNJ14Johnson & Johnson’s Recent Development in HIV ( 6:02:00 AM
JNJ14Johnson & Johnson Expands Blood Cancer Portfolio with Approval ( 4:32:00 AM
JNJ14Johnson & Johnson Seeks EU and US Label Expansion for Darzalex ( 8:15:00 AM
JNJ14Johnson & Johnson: Analyst Recommendations and Target Price ( 5:11:00 AM
JNJ14See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ9Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results ( 1:57:00 PM
JNJ9The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering ( 5:47:00 AM
JNJ9Health care ETF surges toward record in a broad sector rally ( 11:57:00 AM
JNJ9J&J Talc Supplier Takes No Chances on Another Big Jury Loss ( 11:33:00 AM
JNJ9Geron: One of the Best-Performing Biotech Stocks in Past Month ( 6:58:00 AM
JNJ9The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson ( 5:04:00 AM
PG, BA, JNJ77 Dow Jones Stocks Leading the Push to New Highs ( 12:20:00 PM
JNJ4Boston Scientific, Edwards Lifesciences May Tempt J&J ( 5:19:00 PM
JNJ4Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression ( 3:00:00 PM
JNJ4How Does Sage Therapeutics’ Product Portfolio Look in September? ( 10:50:00 AM
JNJ4Is Abbott Laboratories Trading at a High Valuation in September? ( 6:01:00 AM
JNJ4Abbott Laboratories’ 379th Consecutive Quarterly Dividend ( 4:32:00 AM
JNJ4'We're ahead of the pack' in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus ( 3:34:00 PM
JNJ4Here’s a clear case for owning dividend stocks instead of bonds ( 10:43:00 AM
JNJ4Analysts Are Overwhelmingly Bullish on Abbott Laboratories ( 9:17:00 AM
JNJ4Lake Nona appears set to land big biotech facility ( 6:25:00 AM
JNJ4What Quest Diagnostics’ Valuation Trend Indicates ( 4:31:00 AM
JNJ4Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates ( 4:30:00 AM
JNJ4How Quest Diagnostics Is Positioned in 2018 ( 11:53:00 AM
JNJ4Taking Stock of Quest Diagnostics’ Recent Acquisitions ( 11:53:00 AM
JNJ4Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates ( 7:30:00 AM
JNJ4Exclusive - India, U.S. closing in on package deal to remove trade irritants ( 12:44:00 AM
JNJ4Cronos Gets Bigger As It Partners With Ginkgo Bioworks ( 11:09:00 PM
JNJ4Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV ( 3:30:00 PM
JNJ4Pfizer's Skin Disease Candidates Positive in Mid-Stage Study ( 3:27:00 PM
JNJ4Is Artificial Intelligence the Next Big Thing in Biotech? ( 5:19:00 AM
JNJ4Wall Street Analysts Are Mostly Positive on Merck in September ( 2:49:00 PM
JNJ4Pacira Shares Look Expensive, Stifel Says In Bearish Initiation ( 12:55:00 PM
JNJ4Pharma/Biotech Stocks to Watch This Prostate Cancer Month ( 6:43:00 AM
JNJ45 Dow Jones Stocks That Are Gaining New Ground ( 12:35:00 PM
JNJ4Allergan Unveils Spotlyte, Its First Digital Ventures Launch ( 9:52:00 AM
JNJ4City of Boston sues drugmakers over opioid epidemic ( 8:29:00 AM
JNJ4What Analysts Project for Thermo Fisher ( 6:02:00 AM
JNJ4These 13 Stocks Have Raised Their Dividends for 50 Straight Years ( 4:42:00 AM
JNJ4Thermo Fisher to Acquire BDX’s Advanced Bioprocessing Business ( 4:33:00 AM
JNJ4Geron Corp: Lost in Translation? ( 7:27:00 AM
JNJ4Alcon to Set Up Future Global Headquarters in Geneva ( 1:35:00 PM
JNJ4Geron Corporation: A Sober Assessment ( 7:00:00 AM
JNJ4Shire's ADHD Portfolio Remains Strong Amid Competition ( 2:00:00 PM
JNJ4Most Analysts Currently Call Boston Scientific a ‘Buy’ ( 9:41:00 AM
JNJ4The Week Ahead: Apple's Special Event, Mobile World Congress, US Inflation Data On Deck ( 9:17:00 AM
JNJ4Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod ( 6:36:00 AM

WEBSITE DISCLAIMER:  Puget Investors and Vertical Financial Systems, Inc are not registered investment advisers, broker/dealers, or research analysts/organizations. The content on this website is issued solely for information purposes and should not to be construed as an offer to buy, sell, or trade in any way, any security mentioned herein.

All information presented on this website is believed to be reliable and written in good faith, but no representation or warranty, expressed or implied is made as to their accuracy, completeness or correctness. You are responsible for doing your own research before investing in any securities mentioned herein. Readers are urged to consult with their own independent financial advisors with respect to any investment. Neither Vertical Financial Systems, Inc, nor its officers or employees accept any liability whatsoever for any direct or consequential loss arising from any use of information on this website.

Past performance is not a guarantee of future performance or accuracy. Rating calculations and methodology may change at any time, and we reserve the right to make changes which may impact the accuracy of the model without prior notice to anybody.

Be advised that employees and officers of Vertical Financial Systems, Inc and may hold positions in the securities mentioned in this website.
Website Operated by Vertical Financial Systems, Inc